71 results about "Mercaptopurine" patented technology

Personal care composition comprising from about 0.05% to about 5% of at least one aquaporin-stimulating compound selected from the group consisting of xanthine, caffeine; 2-amino-6-methyl-mercaptopurine; 1-methyl xanthine; 2-aminopurine; theophylline; theobromine; adenine; adenosine; kinetin; p-chlorophenoxyacetic acid; 2,4-dichlorophenoxyacetic acid; indole-3-butyric acid; indole-3-acetic acid methyl ester; beta-naphthoxyacetic acid; 2,3,5-triiodobenzoic acid; adenine hemisulfate; n-benzyl-9-(2-tetrahydropyranyl)adenine; 1,3-diphenylurea; 1-phenyl-3-(1,2,3-thiadiazol-5-yl)urea; zeatin; indole-3-acetic acid; 6-benzylaminopurine; alpha-napthaleneacetic acid; 6-2-furoylaminopurine; green tea extract; white tea extract; menthol; tea tree oil; ginsenoside-RB1; ginsenoside-RB3; ginsenoside-RC; ginsenoside-RD; ginsenoside-RE; ginsenoside-RG1; ginseng root extract; ginseng flower extract; pomegranate extract, extracts from Ajuga turkestanica; extracts from viola tricolor and combinations thereof; an additional ingredient selected from the group consisting of niacinamide, glycerin and mixtures thereof, and a dermatologically-acceptable carrier.

The present invention provides a method of optimizing therapeutic efficacy and reducing toxicity associated with 6-mercaptopurine drug treatment of an immune-mediated gastrointestinal disorder such as inflammatory bowel disease. The method of the invention includes the step of determining the level of one or more 6-mercaptopurine metabolites in the patient having an immune-mediated gastrointestinal disorder.

The present invention provides enterically coated formulations of 6-mercaptopurine that exhibit a delay in release of the 6-mercaptopurine such that substantial release of 6-mercaptopurine does not occur until after passage through the stomach. Optionally, the formulations also comprise a delay coating in addition to the enteric coating that provides an even further delay such that substantial release of 6-mercaptopurine does not occur until after a certain period of time following passage through the stomach. Such a period of time is preferably at least one hour after passage through the stomach. Following the delay imparted by the enteric coating and optional delay coating, the formulations exhibit better bioavailability and faster dissolution than previous formulations.

Methods of treating patients suffering from Crohn's disease or ulcerative colitis who did not experience a clinical response to previous thiopurine administration, or suffered side effects from previous thiopurine administration, by administering a delayed release pharmaceutical composition comprising 6-mercaptopurine are disclosed. Methods of treating patients suffering from Crohn's disease or ulcerative colitis who are also being administered a steroid, 5-aminosalicylic acid, or an antibiotic by adjunctively administering a delayed release pharmaceutical composition comprising 6-mercaptopurine are also disclosed.

Methods of administering a delayed release 6-mercaptopurine pharmaceutical composition to patients suffering from inflammatory bowel disease which provide for release of the 6-mercaptopurine after passage of the pharmaceutical composition through the stomach are disclosed. The methods result in significant clinical improvement despite leading to very little systemic absorption of 6-mercaptopurine and also result in very few undesirable side effects.

This invention provides novel peptides and methods to prevent, control, and treat an inflammation, cancer and other disorders, particularly of the gastrointestinal tract and the lung by administering at least one agonist of guanalyte cyclase receptor either alone or in combination with a compound selected from i) 5-aminosalicyclic acid (5-ASA) or a derivative or a pharmaceutically acceptable salt thereof; ii) mercaptopurine; or iii) an anti-TNF therapy.

The present invention provides a method of determining thiopurine methyltransferase (TPMT) activity in a subject. The method includes the steps of reacting sample obtained from the subject with a thiopurine derivative that is not 6-mercaptopurine to produce a methylated purine product; contacting the reacted sample with acid, thereby precipitating proteinaceous material from the reacted sample; separating supernatant from the precipitated proteinaceous material; and detecting in the supernatant the methylated purine product, where the amount of the:methylated purine product indicates a level of thiopurine methyltransferase activity in the subject. In a method of the invention, the subject can be, for example, an inflammatory bowel disease patient. In one embodiment, the acid used to precipitate proteinaceous material is perchloric acid, for example, 70% perchloric acid. In another embodiment, the thiopurine derivative used as a substrate is 6-thioguanine. In a further embodiment, the methylated purine product is detected by fluorescence, which can be combined, if desired, with high performance liquid chromatography (HPLC).

The invention provides a purine drug sensitivity gene chip detection kit belonging to the gene chip technique field of clinical detection, which can be used to parallelly and economically detect genes related to purine drug sensitivity. The kit comprises an extraction solution, a hybridization buffer solution, a washing liquor, an amplifying solution, Taq enzyme and a gene chip, the amplifying solution contains a primer for amplifying genes of three mutant sites on mercaptopurine methyltransferase (TPMT), and the three mutant sites are respectively 238, 460 and 719. The purine drug is used for treating acute lymphoblastic leukemia, and the detection kit can be used to detect the three site mutation conditions of a TMPT gene sensitive to the purine drug.

The present invention relates to methods for optimizing therapeutic efficacy or reducing toxicity in a subject receiving a drug providing 6-thioguanine nucleotide. The methods provide determining 6-thioguanine and 6-methyl-mercaptopurine nucleotide concentration levels using an analytical technique having an ionizing source.

The invention discloses a preparation method for a 6-mercaptopurine molecularly-imprinted electrochemical sensor. The preparation method is characterized by comprising the following steps: modifying a glassy carbon electrode with a silane coupling agent and nanometer platinum; then adding, by mass percentage concentration, 10 to 20% of dimethacrylic acid-1,4-butanediol ester, 8 to 18% of methyl acrylate, 8 to 18% of maleic anhydride, 50 to 60% of N,N-dimethyl formamide 1.0 to 3.0% of dimethyl azodiisobutyrate and 1.0 to 3.0% of 6-mercaptopurine into a reactor, introducing argon for 5 min to remove oxygen and preparing a 6-mercaptopurine molecularly-imprinted polymer in an argon atmosphere; and coating the modified electrode with the polymer and removing template molecule so as to obtain the 6-mercaptopurine molecularly-imprinted electrochemical sensor. The sensor has the advantages of high 6-mercaptopurine recognition performance, low cost, high sensitivity, good specificity, rapid detection, reusability and improved response to 6-mercaptopurine.

The invention discloses a nano-scale mesoporous silica-6-mercaptopurine (6MP)/cisplatin (CDDP) nano-delivery system (MSNS-6MP/CDDP). Its preparation method is disclosed, that is, modifying mercapto groups on mesoporous silica, linking 6MP through disulfide bonds to form mesoporous silica nanoparticles (MSNS‑6MP) connected to 6MP, loading CDDP in the channel to form a link 6MP, CDDP-loaded mesoporous silica nanoparticles; disclosed its nanostructure; disclosed its role in inhibiting tumor growth in S180 mice, compared with conventional 6MP and CDDP combined application, MSNS‑6MP/CDDP significantly prolongs S180 Survival time of mice, improved efficacy and reduced systemic toxicity. Therefore, the invention discloses its application in the preparation of tumor treatment drugs, which has a good application prospect.

The invention discloses a gold nanocluster-based 6-mercaptopurine detection method and a kit. With use of specific interaction of carboxylated chitosan-dithiothreitol-gold nanoclusters and 6-mercaptopurine, fluorescence of the carboxylated chitosan-dithiothreitol-gold nanoclusters is quenched, and a carboxylated chitosan-dithiothreitol-gold nanocluster solution is added to a phosphate buffer solution containing 6-mercaptopurine; with increasing of the concentration of 6-mercaptopurine, the fluorescence intensity value F650 of the carboxylated chitosan-dithiothreitol-gold nanoclusters at 650 nmis decreased, so that the content of 6-mercaptopurine is determined. The invention provides a new detection method for 6-mercaptopurine, wherein the method has the advantages of high test sensitivity, good specificity, good accuracy, simple detection process, good stability, simple operation, short detection time, high sensitivity, strong specificity and the like.

A therapeutic formulation comprising a microemulsion of a therapeutic agent in free and/or conjugatively coupled form, wherein the microemulsion comprises a water-in-oil (w/o) microemulsion including a lipophilic phase and a hydrophilic phase, and has a hydrophilic and lipophilic balance (HLB) value between 3 and 7, wherein the therapeutic agent may for example be selected from the group consisting of insulin, calcitonin, ACTH, glucagon, somatostatin, somatotropin, somatomedin, parathyroid honnone, erythropoietin, hypothalamic releasing factors, prolactin, thyroid stimulating hormones, endorphins, enkephalins, vasopressin, non-naturally occurring opioids, superoxide dismutase, interferon, asparaginase, arginase, arginine deaminease, adenosine deaminase, ribonuclease, trypsin, chymotrypsin, papain, Ara-A (Arabinofuranosyladenine), Acylguanosine, Nordeoxyguanosine, Azidothym id ine, Didesoxyadenosine, Dideoxycytidine, Dideoxyinosine Floxuridine, 6-Mercaptopurine, Doxorubicin, Daunorubicin, or I-darubicin, Erythromycin, Vancomycin, oleandomycin, Ampicillin; Quinidine and Heparin. In a particular aspect, the invention comprises an insulin composition suitable for parenteral as well as non-parenteral administration, preferably oral or parenteral administration, comprising insulin covalently coupled with a polymer including (i) a linear polyalkylene glycol moiety and (ii) a lipophilic moiety, wherein the insulin, the linear polyalkylene glycol moiety and the lipophilic moiety are conformationally arranged in relation to one another such that the insulin in the composition has an enhanced in vivo resistance to enzymatic degradation, relative to insulin alone. The microemulsion compositions of the invention are usefully employed in therapeutic as well as non-therapeutic, e.g., diagnostic, applications.

The invention relates to an antitumor composition and application thereof in preparation of an antitumor medicine or a medicine for inhibiting cancer cells, as well as the antitumor medicine, and belongs to the technical field of medicine preparation. The antitumor composition involved in the invention comprises a first antitumor component and a second antitumor component; the first antitumor component is one or two of mercaptopurine and thioguanine or a salt or salts of one or two of the mercaptopurine and the thioguanine; the second antitumor component is dihydroartemisinin, and the molar ratio of the first antitumor component to the dihydroartemisinin is 1:(1-4); or the second antitumor component is an artemisinin derivative, and the molar ratio of the first antitumor component to artemisinin or the dihydroartemisinin generated through metabolism of the second antitumor component is 1:(1-4); and an antitumor compound capable of generating the dihydroartemisinin through metabolism isone or a combination of several of artesunate, artemether and arteether. The two antitumor components of the antitumor composition involved in the invention have a synergy effect.

The invention discloses a 6-(beta-alkylnaphthy)mercaptopurine compound of which the structural formula is disclosed in the specification. The 6-(beta-alkylnaphthy)mercaptopurine compound can inhibit growth of cancer cells. The invention also discloses a synthesis method and application of the 6-(beta-alkylnaphthy)mercaptopurine compound. The synthesis method has the advantages of simple synthesis steps and higher yield, and is suitable for industrial production. The 6-(beta-alkylnaphthy)mercaptopurine compound disclosed by the invention is used for inhibiting cancer cells, and has obvious effect.

A liquid pharmaceutical composition for use in the treatment of acute lymphoblastic leukaemia (ALL) comprising 6-mercaptopurine or a salt, hydrate or solvate thereof and a pharmaceutically-acceptable excipient, wherein the composition is a suspension for oral administration, a kit of parts for the accurate dosing and administration of the liquid pharmaceutical composition, and a method for the treatment of ALL in a human patient comprising administration of a therapeutically effective amount of the liquid pharmaceutical composition.